<DOC>
	<DOCNO>NCT02471144</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo- active-controlled ( etanercept single blind arm ) study pediatric subject age 6 year less 18 year severe chronic plaque psoriasis . Approximately 160 subject age 6 year &lt; 18 year enrol , least 30 6 year &lt; 12 year old . It expect subject enrol approximately 70 study site worldwide .</brief_summary>
	<brief_title>Pediatric Study Children Adolescents With Severe Plaque Psoriasis</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo- active-controlled ( etanercept single blind arm ) study pediatric subject age 6 year less 18 year severe chronic plaque psoriasis . Approximately 160 subject age 6 year &lt; 18 year enrol , least 30 6 year &lt; 12 year old . It expect subject enrol approximately 70 study site worldwide . The purpose study demonstrate superior efficacy secukinumab versus placebo Week 12 , base PASI 75 IGA mod 2011 0 1 response rate child adolescent age 6 less 18 year severe chronic plaque psoriasis inadequate control symptoms topical treatment , fail respond tolerate previous systemic treatment and/or UV therapy . The study ass long term safety tolerability secukinumab pediatric age group describe efficacy safety secukinumab compare etanercept . This study provide efficacy safety data support extension label secukinumab include child adolescent ( 6 year &lt; 18 year ) severe chronic plaque psoriasis Two age subgroup study staggered approach within clinical study : 12 less 18 year age , 6 less 12 year age . Enrolment child age 6 less 12 year begin favorable recommendation independent external Data Monitoring Committee ( DMC ) review data approximately 80 adolescent . Adolescents continue recruit data first 80 subject collect analyzed . Subjects randomize use 1:1:1:1 ratio one treatment arm : secukinumab low dose , secukinumab high dose , etanercept placebo . Subjects randomize secukinumab treatment arm ( high dose low dose ) receive dose base weight category ( &lt; 25 kg , 25 &lt; 50kg , â‰¥50 kg ) . The study consist 5 period : screening ( 4 week ) , induction ( 12 week ) , maintenance ( 40 week ) , extension treatment epoch ( open-label 184 week ) post- treatment follow-up epoch ( 16 week ) . The primary objectiove study demonstrate superiority secukinumab ( low high dose ) pediatric subject severe chronic plaque psoriasis respect PASI 75 IGA mod 2011 0 1 response ( co-primary endpoint ) Week 12 , compare placebo</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion criterion : Must 6 less 18 year age time randomization Plaquetype psoriasis history least 3 month . Severe plaquetype psoriasis meeting follow three criterion : PASI score 20 great , Investigator 's Global Assessment ( IGA ) score 4 Total body surface area ( BSA ) affect 10 % great . Patient regard investigator candidate systemic therapy : 1. inadequate control symptoms topical treatment , 2. failure respond tolerate previous systemic treatment and/or UV therapy Exclusion criterion : Current form psoriasis chronic plaquetype psoriasis ( example , pustular , erythrodermic , guttate ) randomization . Current druginduced psoriasis . Previous use secukinumab drug target IL17 IL17 receptor . Underlying condition ( include , limited metabolic , hematologic , renal , hepatic , pulmonary , neurologic , endocrine , cardiac , infectious gastrointestinal ) opinion investigator significantly immunocompromises subject and/or place subject unacceptable risk receive immunomodulatory therapy History ongoing , chronic recurrent infectious disease , evidence untreated tuberculosis . History lymphoproliferative disease history malignancy organ system within past 5 year . Pregnant nursing ( lactate ) woman . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pediatric , chronic severe plaque psoriasis , secukinumab , etanercept</keyword>
</DOC>